Physician profile
Daniel P Walker
NPI 1669731519
$235,390.74
in general payments reported to CMS, 2019-2025
43 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,669 · 2020: $3,051 · 2021: $23K · 2022: $55K · 2023: $70K · 2024: $49K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Food and Beverage: $18K · Consulting Fee: $12K · Travel and Lodging: $3,260 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,939.00 |
| Food and Beverage | $18,119.72 |
| Consulting Fee | $12,237.50 |
| Travel and Lodging | $3,260.20 |
| Education | $297.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140,926.23 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Lilly USA, LLC | $56,452.01 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $9,661.29 | 2019-2025 | |
| Janssen Biotech, INC. | $5,656.36 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $5,433.54 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $2,158.52 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $2,055.27 | 2023-2025 | Zoryve |
| Genzyme Corporation | $1,948.66 | 2019-2025 | |
| Amgen INC. | $1,837.38 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $1,396.54 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,262.67 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $993.73 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $721.91 | 2020-2024 | Siliq, Targretin, Duobrii |
| Incyte Corporation | $707.01 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $547.48 | 2022-2024 | Vtama |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $547.38 | 2019 | |
| Mayne Pharma Commercial LLC | $525.93 | 2019-2025 | |
| Leo Pharma INC. | $511.29 | 2020-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $473.30 | 2022-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $287.17 | 2020-2021 | |
| Organon LLC | $272.49 | 2023-2025 | Hadlima, Vtama |
| Medimetriks Pharmaceuticals, INC. | $207.50 | 2019-2021 | |
| Almirall LLC | $116.65 | 2019-2025 | Seysara, Klisyri |
| Journey Medical Corporation | $113.02 | 2020-2025 | |
| Dermira, INC. | $70.10 | 2020-2021 | |
| Elekta, INC. | $63.99 | 2023 | Elekta Medical Linear Accelerator |
| Biofrontera INC. | $56.89 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Paratek Pharmaceuticals, INC. | $51.14 | 2021-2023 | Nuzyra |
| Abbott Laboratories | $40.73 | 2020 | |
| Allergan, INC. | $40.49 | 2021-2022 | |
| Promius Pharma LLC | $35.70 | 2019 | |
| Merck Sharp & Dohme LLC | $27.48 | 2019 | |
| Blueprint Medicines Corporation | $27.31 | 2025 | Ayvakit |
| Glenmark Therapeutics INC. | $22.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.52 | 2025 | Spevigo |
| Medtronic, INC. | $18.63 | 2021 | |
| Botanix Sb INC | $17.30 | 2025 | Sofdra |
| Genentech USA, INC. | $16.86 | 2021 | |
| Dusa Pharmaceuticals, INC. | $15.92 | 2019 | |
| Kyowa Kirin, INC. | $15.06 | 2025 | |
| Mylan Pharmaceuticals INC. | $14.54 | 2019 | |
| Prugen, INC. Pharmaceuticals | $12.57 | 2019 | |
| Tactile Systems Technology INC | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.